CL2015001157A1 - Composiciones y métodos para tratar proteinopatías. - Google Patents

Composiciones y métodos para tratar proteinopatías.

Info

Publication number
CL2015001157A1
CL2015001157A1 CL2015001157A CL2015001157A CL2015001157A1 CL 2015001157 A1 CL2015001157 A1 CL 2015001157A1 CL 2015001157 A CL2015001157 A CL 2015001157A CL 2015001157 A CL2015001157 A CL 2015001157A CL 2015001157 A1 CL2015001157 A1 CL 2015001157A1
Authority
CL
Chile
Prior art keywords
proteinopathies
treat
compositions
methods
treat proteinopathies
Prior art date
Application number
CL2015001157A
Other languages
English (en)
Inventor
Sergio Pablo Sardi
Lamya Shihabuddin
Seng Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49578599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001157(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CL2015001157A1 publication Critical patent/CL2015001157A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
CL2015001157A 2012-11-05 2015-04-30 Composiciones y métodos para tratar proteinopatías. CL2015001157A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261722434P 2012-11-05 2012-11-05

Publications (1)

Publication Number Publication Date
CL2015001157A1 true CL2015001157A1 (es) 2015-10-16

Family

ID=49578599

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001157A CL2015001157A1 (es) 2012-11-05 2015-04-30 Composiciones y métodos para tratar proteinopatías.

Country Status (22)

Country Link
US (1) US20150284472A1 (es)
EP (1) EP2914281A1 (es)
JP (1) JP2016503405A (es)
KR (1) KR20150079751A (es)
CN (1) CN104902923A (es)
AR (1) AR093355A1 (es)
AU (1) AU2013337354A1 (es)
BR (1) BR112015009746A2 (es)
CA (1) CA2889990A1 (es)
CL (1) CL2015001157A1 (es)
CR (1) CR20150216A (es)
EA (1) EA201590880A1 (es)
HK (1) HK1214521A1 (es)
IL (1) IL238416A0 (es)
MA (1) MA38144A1 (es)
MX (1) MX2015005722A (es)
PH (1) PH12015500879A1 (es)
SG (1) SG11201502989XA (es)
TN (1) TN2015000171A1 (es)
TW (1) TW201427695A (es)
WO (1) WO2014071282A1 (es)
ZA (1) ZA201502618B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024895B8 (pt) 2008-06-26 2021-07-27 Orphazyme As uso de um agente bioativo capaz de aumentar a concentração intracelular de hsp70
EP3626255A1 (en) 2010-11-30 2020-03-25 Orphazyme A/S Methods for increasing intracellular activity of hsp70
ES2881860T3 (es) 2014-09-15 2021-11-30 Orphazyme As Formulación de arimoclomol
AU2016256895B2 (en) * 2015-05-07 2022-05-26 Takeda Pharmaceutical Company Limited Glucocerebrosidase gene therapy for parkinson's disease
SG10202100652VA (en) * 2015-07-21 2021-03-30 Univ Jefferson Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
LT3448382T (lt) * 2016-04-29 2021-04-12 Orphazyme A/S Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti
EP3264092A1 (en) * 2016-07-01 2018-01-03 Centogene AG Use of lyso-gb1 as druggable target
IL264603B2 (en) * 2016-08-03 2023-10-01 Univ South Florida REELIN preparations for the treatment of neurological diseases
US11807849B2 (en) 2017-10-03 2023-11-07 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
KR20200078512A (ko) * 2017-10-03 2020-07-01 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
KR20220015499A (ko) * 2017-10-03 2022-02-08 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
US20210261981A1 (en) * 2017-10-23 2021-08-26 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative diseases
AU2018354318A1 (en) * 2017-10-26 2020-04-23 Takeda Pharmaceutical Company Limited Formulations comprising glucocerebrosidase and isofagomine
EP3765855A1 (en) * 2018-03-14 2021-01-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Detection of phospho-serine 129 alpha-synuclein in blood cells as a biomarker for synucleinopathies
EP3953378A1 (en) * 2019-04-10 2022-02-16 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
EP3986412A4 (en) * 2019-06-21 2023-11-15 The Broad Institute, Inc. AGENTS TO REVERSE TOXIC PROTEINOPATHIES
CN116390773A (zh) 2020-08-06 2023-07-04 应用医学研究基金会 用于通过基因疗法治疗诸如阿尔茨海默病的Tau蛋白病的病毒颗粒
AU2021380947B2 (en) 2020-11-19 2023-12-14 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
CN112569354B (zh) * 2020-12-29 2022-06-10 四川大学华西医院 tau蛋白及其基因作为药物靶点在制备治疗糖尿病药物中的应用
WO2023111336A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Oligonucleotide gba agonists
WO2023111335A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Oligonucleotides capable of increasing glucocerebrosidase expression

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2166118C (en) 1993-06-24 2007-04-17 Frank L. Graham Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
DE60044997D1 (de) 1999-07-02 2010-11-04 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
EP1204739B1 (en) 1999-08-09 2008-08-06 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
DE60117550T2 (de) 2000-06-01 2006-12-07 University Of North Carolina At Chapel Hill Doppelsträngige parvovirus-vektoren
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
PT2040548E (pt) * 2006-06-23 2012-08-02 Amicus Therapeutics Inc Método para o tratamento de distúrbios neurológicos através do aumento da atividade da -glucocerebrosidase
EP3000320B1 (en) * 2007-05-16 2019-01-16 The Brigham and Women's Hospital, Inc. Treatment of synucleinopathies
JP6061922B2 (ja) 2011-06-22 2017-01-18 ザ ジェネラル ホスピタル コーポレイション プロテイノパチーの処置方法
CA2868484A1 (en) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salicylic acid derivatives useful as glucocerebrosidase activators

Also Published As

Publication number Publication date
CA2889990A1 (en) 2014-05-08
MX2015005722A (es) 2016-01-12
US20150284472A1 (en) 2015-10-08
ZA201502618B (en) 2016-01-27
HK1214521A1 (zh) 2016-07-29
IL238416A0 (en) 2015-06-30
BR112015009746A2 (pt) 2017-08-15
WO2014071282A1 (en) 2014-05-08
TN2015000171A1 (fr) 2016-10-03
KR20150079751A (ko) 2015-07-08
AU2013337354A1 (en) 2015-05-21
JP2016503405A (ja) 2016-02-04
CR20150216A (es) 2015-05-29
EA201590880A1 (ru) 2015-09-30
TW201427695A (zh) 2014-07-16
EP2914281A1 (en) 2015-09-09
PH12015500879A1 (en) 2015-06-29
MA38144A1 (fr) 2018-08-31
AR093355A1 (es) 2015-06-03
CN104902923A (zh) 2015-09-09
SG11201502989XA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
LTPA2021003I1 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su KIT
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
BR112015003354A8 (pt) métodos e composições de microcápsula
CL2014003386A1 (es) Métodos y composiciones para producción de biometano
BR112015003227A2 (pt) processos de clicoconjugação e composições
DK3590358T3 (da) Næringsmiddelsammensætning
DK2911506T3 (da) Driftreducerende sammensætninger
BR112015010947A2 (pt) composições e métodos para aumentar o metabolismo energético.
BR112015005011A2 (pt) métodos e composições para produzir hepatócitos induzidos.
BR112015002651A2 (pt) composições cosméticas
BR112014032798A2 (pt) composição
CL2014002051A1 (es) Composiciones plaguicidas y procesos relacionados con dichas composiones
BR112015001562A2 (pt) biotinas e composições
CL2015000049A1 (es) Método y composición para secuestrar arsénico.
BR112014020547A2 (pt) composições oleosas e métodos de produção
BR112014022694A2 (pt) novos métodos e composições para o tratamento de doença
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112015007217A2 (pt) compostos e usos do composto
BR302013000341S1 (pt) Configuração aplicada em aplicador para cosméticos
BR112015014884A2 (pt) método para identificar, polinucleotídeo isolado e kit
BR112014032712A2 (pt) composição
DE112013005825A5 (de) Reduktionsmittelzuführeinrichtung
DK2811828T3 (da) Adjuvanssammensætninger
BR112015013877A2 (pt) método, e, composição
DK2800573T3 (da) Oftalmologisk sammensætning